Life Sciences and Industry Magazine

Summer Edition 2018 | Volume 17 | 20 €

ISSN 2364-2351 | A 60711 |

NanobotsMicroscopic drug delivery systems – the next big thing

AgrochemistryBayer-Monsanto to bet on genome editing in crop design

BioeconomyGlobal policy leaders lay out agenda to push biologisation

Biofairs CompassThe ultimate guide to leading Life Sciences Events in H2/2018

Fixing the leak

InterviewNovartis CEO Vasant Narasimhanreveals why he bets on one-time curative treatmentsand digital tools

Haemophilia A FREE EXCERPT

Don´t prepare. Just be ready.

The new C2MAP-2000 automates all steps frompretreatment to measurement without any humanintervention. It simplifies the workflow for optimiz-ing cell culture conditions. There is no need to prepare. Just be ready.

Complete LCMS solution for cell culture analysiscombining the C2MAP-2000 pretreatment modulewith ultra-fast LCMS-8060

Highly efficientthrough cutting culture media analysis time by 80 percent

Monitoring of up to 95 components including amino acids, metabolites, sugars, vitaminsand organic acids

Changes at a glancewith C2MAP-TRENDS viewer software visualizing temporal changes of components

www.shimadzu.eu/c2map

C2MAP-2000 – 1 method, 17 mins, 95 media components

C2MAP-2000 – Complete LCMS solution

Shimadzu_Euro-Bio-Tech_2018:00 09.05.18 10:14 Seite 1

3IntroEuropean Biotechnology | Summer Edition | Vol. 17 | 2018

Pict

ure:

Nov

a Ins

titut

e, C

olog

ne

Plastics are magical materials, and they will be even more impor-tant in the future than they are today. But they lead to microplas-tics in the environment, especially noticeable as “marine littering.” The European Commission is now proposing, among other things, a ban on certain single-use plastic products, including “plastic cotton buds, cutlery, plates, straws, drink stirrers, and sticks for balloons, which will all have to be made exclusively from more sustainable materials instead.” The Commission’s legislative proposal must then be negotiated with the member states and the European Parliament. And here substantial changes should still be made – because so far industry and politics continued to fail in this area.

Microplastics have been in the public eye for at least ten years.The plastics industry has waited until the public pressure be-came too high to ignore. Then their argument was, what can our plastics do if people do not handle our products properly and politicians do not organise better recycling programmes? But in fact, the plastics industry can do something about it. For years, there has been another solution for plastic products that are practically impossible to recycle or whose preparation is far too costly: biodegradable plastics.

The European Commission has spent several million Euros over the last ten years to develop and certify such plastics. Plastics that are biodegradable in water, soil, home compost or indus-trial composting and do not leave any microparticles behind. And today there are many producers of biodegradable plas-tics; there are certifications and labels. But these new plastics are still a little too expensive to become sure-fire success. And now they don’t even get a chance in the new European plas-tics strategy!

Seize the opportunity for innovation and sustainability now. We prohibit single-use products if they are not biodegradable. But let us give biodegradable plastics, which have been successfully developed for years, their chance on the market! We also need alternatives to plastic products that, even when used properly, end up in the environ-ment and are difficult or impossible to recycle. A few examples would be mulch films, tree protection covers, plant clips, binding yarns, strings for lawn trimmers, carrier pol-ymers for fertilizers and pesticides, and even plastic baits at sea. Let us take a step for-ward in all of Europe. Because now is the time when the rules for the coming decades are being made.

Further reading: http://bio-based.eu/policy/#innprobiofacts

Single-use plastics: New EU rules to reduce marine litter

Michael carus The founder and Managing Director of the nova-Institute studied physics and mathematics at the University of Cologne. Carus became a lecturer at the University of Tübingen, on the topics of ecology, nuclear energy, and radioactivity. He worked as a science journalist and scientist at the KATALYSE Environmental Institute with a focus on energy, ecology, and renewable resources, and two years in the solar industry. In 1994, he founded the nova-Institute for Ecology and Innovation.

FREE EXCERPT

4 Contents european Biotechnology | summer edition | Vol. 17 | 2018Contents

InsIght EuropE

6 User-driven early certainty: ePo steps back

10 Launch of european PnAs; More rights for european CDMos

11 european Commission proposes €100m budget for Horizon europe

Economy

17 Interview (Haemophilia): Gallia Levy, Global Development team Leader, Hemlibra, Roche AG

19 Update on clinical trials

22 Interview (strategy): Vas narasimhan, Ceo, novartis AG

24 eMA news

25 Analyst commentary

26 euro Biotech stocks

28 Interview (Bioeconomy Finance): Rob Carlson, Managing Director, Bioeconomy Capital

30 Headwinds in sustainable industry and manufacturing

33 Falsified medicines deadline nears

34 Interview; Hannes teissl, Polpharma Biologics

36 Interview: Federico Pollano, Rentschler Biopharma

Stopping the bleed

covEr story

since factor VIII replacement therapies hit the market, life expectancy for haemo-philia patients has risen to normal levels. But around 25% of those who suffer from haemophilia A still have no therapeutic options, because their immune systems form antibodies against clotting prod-ucts that can stop bleeding. Researchers and companies in the growing Us$15bn haemo philia medications market are fe-verishly exploring new ways to identi-fy patients at risk and offer them alterna-tive treatments, while a series of mergers and acquisitions have changed the playing field for established markets and players.

IMPRInt european Biotechnology (Issn 2364-2351) is published quarterly by: BIoCoM AG, Lützowstr. 33–36, D-10785 Berlin, Germany, tel.: +49-30-264921-0, Fax: +49-30-264921-11,

email: service@european-biotechnology.com, Internet: www.european-biotechnology.com; Publisher: Andreas Mietzsch; editorial team: thomas Gabrielczyk (editor in Chief), Derrick Williams (Co-

editor), Dr. Martin Laqua, Helene Märzhäuser, sandra Wirsching; Advertising: oliver schnell, +49-30-2649-2145, Christian Böhm, +49-30-2649-2149, Andreas Macht, +49-30-2649-2154; Distribution:

Marcus Laschke, +49-30-2649-2148; Graphic Design: oliver-sven Reblin; Production editor: Benjamin Röbig; Printed at: Königsdruck, Berlin; european Biotechnology Life sciences &

Industry Magazine is only regularly available through subscription at BIoCoM AG. Annual subscription fees: € 80.00, students € 40.00 (subject to proof of enrolment). Prices include VAt, postage

& packaging. ordered subscriptions can be cancelled within two weeks directly at BIoCoM AG. the subscription is initially valid for one year. subscriptions will be renewed automatically for one

more year, respectively, unless they are cancelled at least six weeks before the date of expiry. Failures of delivery, which BIoCoM AG is not responsible for, do not entitle the subscriber to delivery or

reimbursement of pre-paid fees. seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material

published is protected by copyright. no article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the

publisher. Cover Photo: naeblys/istockphoto.com; supplement: AseBIo, eFIB/BIoCoM; ® BIoCoM is a registered trademark of BIoCoM AG, Berlin, Germany.

12

rEgIonal nEws

66 northern europe: sweden, Denmark, norway

and Finland

68 Western europe: France, Belgium, the netherlands and the UK 70 Central europe: Germany, switzerland and Austria

72 southern europe: Italy, spain, Greece, slovenia, and Greece

74 eastern europe: Poland, Czech Republic and Hungary

scIEncE & tEchnology

80 First mesenchymal stem cell therapy hits the european market

82 Approved diabetes medicine helps PAH patients

sErvIcE

75 Biopeople84 news from partner associations:

swiss Biotech Association, Medtec europe and europa Bio

88 events 89 Company index/new products90 encore

Pict

ure:

Nae

blys

/ist

ockp

hoto

.com

FREE EXCERPT

5Contentseuropean Biotechnology | summer edition | Vol. 17 | 2018

agrI-bIotEch

Consolidation up topthey co-created Agent orange. now agri-biotech giants Bayer and Monsanto are about to merge into a single mega-entity for pushing genetic engineering technologies in the crop design market. EuropEan BiotEchnology takes a look at what consumers and farmers can expect, and how new products will be regulated in the age of the ‘Big Four’.

Contents

EdItorIal

Global discharge At the recent Global Bioeconomy Summit (see. p. 30), US researcher John Schramski had an interesting message. He sees our planet as an accumulator that’s been charged up by hundreds of millions of years of photosynthesis. Until now, he said, Earth has been able to effortlessly top up reserves. But as energy consumption by humans exploded over the past century, its currency of biomass and fossil fuel has been almost fully depleted. “We have to slow down,“ Schramski warns – because without our natural resources we won’t survive.

An interesting aspect of the international meeting was that two major lobbies were apparent. There were those who pushed the idea that we all need to focus on sustainability, because no one knows how much longer we can go on exploiting our planet (see p. 32). On the other side were those who primarily see the economic opportunities attached to green technology (see p. 28).

Maybe biologisation of the industry is about both. Making money, but with the right biotechnologies for rebalancing economic, social and ecological imbalances.

The challenge now is to separate those who tout old technology to make money under green labels from those offering the right solutions.

thomas Gabrielczyk

editor-in-Chief

76

drug dElIvEry

60

SPECIAL

Event compass

Pict

ures

: ior

dani

/fot

olia

.com

(top

), lo

nero

c/sh

utte

rsto

ck.c

om (m

iddl

e), A

BLin

c. (b

otto

m)

Nanobot healthcarethey’re small, fast – and could be the fu-ture of medicine. nanobots have already been used in animal trials to attack tu-mours, and have proven effective. But there are still a few problems to over-come before doctors begin injecting mil-lions of tiny machines into humans. not least that researchers still have to figure out how to get rid of the microscopic helpers once they’ve done their job.

39 Intro: update on EU events40 NLS Days, Stockholm42 European Biotech Week 44 Biospain, Seville46 bioLIVE, Madrid48 BIO Japan, Yokohama50 EFIB, Toulouse52 European Business Development

Conference, Hanover, Germany54 BIO Europe, Copenhagen56 Pharmalab, Düsseldorf58 Biofit, Lille

FREE EXCERPT

12 European Biotechnology | Winter Edition | Vol. 16 | 2017RuBRik

Pict

ures

: xxx

13European Biotechnology | Summer Edition | Vol. 17 | 2018

Pict

ures

: PEI

(rig

ht),

selv

aneg

ra/i

stoc

kpho

to.c

om (l

eft)

HAEmAtology

Closing the gap in haemophilia therapyFactor VIII InhIbItors About 25% of the people who suffer from haemophilia A have no

therapeutic options, because their immune system forms antibodies against clotting products that

can stop bleeding. Researchers and companies in the growing US$15.8bn haemophilia market are

feverishly exploring new ways to identify patients at risk and offer them alternative treatments. A

series of mergers and acquisitions have changed the playing field for established markets and players.

Every time michael fell when he was a child, his parents had to rush him to the hospital. “Between the ages of one and six, we were

there pretty much every day,” his moth-er remembers. Her son is one of 320,000 people worldwide with haemophilia A, the more common form of the genetic condi-tion. People living with the hereditary dis-ease either don’t produce enough of a clot-ting protein called factor Viii, or they lack it completely. Because their blood doesn’t clot properly, it can lead to uncontrolled bleeding. the disease is called ‘mild’ when FViii levels are 5%-40% of normal levels, ‘moderate’ when between 1%-5%, and ‘severe’ when they’re under 1%. michael has the severe form. injections with fac-tor Viii, the current standard of care, can prevent and treat bleeding episodes. “i try to do what i can, and not spend too much time thinking about what i can’t do,” says michael, now a young man. “For me, that’s a kind of motto in life.” Starting in the 1950s, prophylactic factor Viii infusions were derived to treat haemophiliacs with plasma-derived factor Viii products from donors. in the 1990s, complement ary treat-ments with recombinant factor Viii proteins hit the scene. Prophylactic factor Viii re-placement therapy has now cut the aver-age number of bleeds from more than 40 a year to under two. today, a child born with severe haemophilia can expect to have a normal lifespan. But besides annual treat-ment costs of uS$150,000-$300,000 per

? �Why�is�it�important�to�find�factors�in the blood that boost factor Viii inhibitor formation?

! It’s a prerequisite for developing new approaches to haemophilia therapies, which prevent the for-mation of these inhibitors against factor-VIII products.

Zoe Waibler Head Product assessor for immunologic Drugs, Paul ehrlich institute, langen (Germany)

patient, other serious hurdles remain. Prophylactic therapy patients continue to need drugs that will decrease their need for immuno suppressants. the half-life of the active factor Viii protein is also short, and needs to be extended. And most im-portantly, a significant number of pa-tients simply don’t respond to treatment. Almost one in three people with severe haemophilia A also develops inhibitors –

antibodies that identify the recombinant blood clotting factor Viii as foreign, and stop it from working. For the big players in�the�currently�US$15.8bn�field�–�Shire,�Biogen/Bioverativ,�Novo�Nordisk,�Pfizer�and others (see table, p. 14) – new ap-proaches to solving those problems could have a big impact on revenues. the mar-ket is growing. Analysts from transparen-cy market Research predict it will surpass uS$25bn by 2024.

the huge unmet medical need and as-sociated potential has triggered major ac-quisitions, with former market leaders un-der new ownership. Biogen haemophilia spinout Bioverativ, for instance, was tak-en over by Sanofi for uS$11.8bn. in a uS$62bn acquisition, haemophilia amd haematology giant Shire plc agreed in may to a takeover by takeda. Approach-es for circumventing the immuno genicity and inhibitor problem – such as factor Viii products with fully human glycosylation patterns,�gene�therapies�or�bi�specific�anti-bodies that mimic the effects of factor Viii with less or no potential for inhibitor for-mation – have the potential to change the field�dramatically.

Predicting inhibitor formation

However, current claims involving re-duced immunogenicity and reduced […]

›› read the full story in the printed issue.

FREE EXCERPT

60 European Biotechnology | Summer Edition | Vol. 17 | 2018

Pict

ures

: Bio

desig

n In

stitu

te, A

rizon

a Sta

te U

nive

rsity

Drug DEliVEry

Nanobots: Fiction becoming realityDrug Delivery Once confined to speculative and science fiction, miniature micro- or

nanobots targeting pathogens or conditions directly have now become reality in research labs

worldwide. But to enter clinical trials, scientists still have to overcome two major hurdles –

visualising the tiny machines inside the body, and preventing a potential immune response.

›› Read the full story in the printed issue.

FREE EXCERPT

76 Agriculture

Pict

ure:

foto

lia.d

e/Va

lent

inVa

lkov

european Biotechnology | Summer edition | Vol. 17 | 2018

The future of agrochemistry Pesticides & seeds One of the world’s largest and most controversial mergers in the past few

years was sealed in early June. German pharma and chemistry company Bayer has taken over US

competitor Monsanto, forming the largest integrated provider of seeds, agrochemicals and digital

farming solutions on the planet. The acquisition is part of a recent US$170bn deal binge that is al-

ready having a profound impact on the future of global agriculture.

›› Read the full story in the printed issue.

A tractor entailing a fog of pesticides – a rare sight in a couple of years? Precision distribution of crop protecting agents via for instance drones could soon usher out mass spraying.

FREE EXCERPT

89European Biotechnology | Summer Edition | Vol. 17 | 2018

Pict

ures

: Pro

moC

ell

company indEx/product

3p Biopharmaceuticals S.L. (ES) . . . . . . . . . . . . . . . . . . . 67

abcam (uK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 69ablynx (B) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25adama (iL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 78adc therapeutics SaS (cH) . . . . . . . . . . . . . . . . . . . . . . 20Affiris AG (AT). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70Aldevron GmbH (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . . 75alexion pharmaceuticals (uSa) . . . . . . . . . . . . . . . . . . . 67amgen Europe B.V. (cH). . . . . . . . . . . . . . . . . . . . . . . . . 24amplidiag oy (Fi) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67anergis Sa (cH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70aSEBio (ES) . . . . . . . . . . . . . . . . . . . . . . . . 45, Supplementasit Biotech Sa (B) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25astraZeneca aB (SE/uK) . . . . . . . . . . . . . . . . . . . . . . . . . 19avexis inc. (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 71

BASF AG (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 78, 79Bayer AG (DE) . . . . . . . . . . . . . . . . . 19, 21, 25, 77, 78, 79Bia Separations d.o.o. (SLo) . . . . . . . . . . . . . . . . . . . . . . 73BIOCOM AG (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . cp3BioFit 2018 (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59Biogen idec (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 71Biognosys AG (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65BioJapan 2018 (Jp) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49Biological industries (Bi) Ltd. (uSa) . . . . . . . . . . . . . . . . 83Biomarin pharmaceuticals (uSa) . . . . . . . . . . . . . . . . . . 16Biomay AG (AT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73Bioverativ (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Biovertis AG (AT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68bluebird bio (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 71Boehringer ingelheim (dE) . . . . . . . . . . . . . . . . . . . . . . . 69

CANDOR Bioscience GmbH (DE) . . . . . . . . . . . . . . . . . 23capital cell (ES) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73cara therapeutics (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . 70cargill inc. (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79cassiopea Spa (it) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70celgene corp. (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . . 71cellectis (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25chemchina (cn) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77chugai pharma Europe Ltd. (uK) . . . . . . . . . . . . . . . . . . 17Citoxlab Group (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74clovis oncology uK Ltd. . . . . . . . . . . . . . . . . . . . . . . . . 24coca-cola (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10concept Heidelberg (dE) . . . . . . . . . . . . . . . . . . . . . . . . 57cosmo pharmaceuticals nV (nL) . . . . . . . . . . . . . . . . . . 21cphi / BioLive 2018 (nL) . . . . . . . . . . . . . . . . . . . . . . . . 47criSpr therapeutics (cH/uSa) . . . . . . . . . . . . . . . . . . . 20cynata Ltd. (au) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82

deinove Sa (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68DGPharMed/DGPharmMed Annual Meeting 2019 (DE) . 38dowdupont (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77Dunn Labortechnik GmbH (GER . . . . . . . . . . . . . . . . . . 11Dynabind GmbH (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . 74

EFiB 2018 (B) . . . . . . . . . . . . . . . . . . . . . . . 51, SupplementEBD Group (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55Eppendorf AG - Bioprocess Center Europe (DE) . . . . . . . . 7EuropaBio /European Biotech Week (Eu) . . . . . . . . . . . . 43European Business dev. conf. 2018 (dE) . . . . . . . . . . . . 53Evotec AG (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71Exelixis, inc. (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

FESia (ES) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73FGK Clinical Research GmbH (DE) . . . . . . . . . . . . . . . . . 18Fmc agricultural Solutions (uSa) . . . . . . . . . . . . . . . 77, 78Freenome inc. (uSa). . . . . . . . . . . . . . . . . . . . . . . . . . . . 71

Genentech Inc. (USA) . . . . . . . . . . . . . . . . . . . . . 17, 20, 21Genewave SAS (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67Genmab A/S (DK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20GenSight Biologics (F) . . . . . . . . . . . . . . . . . . . . . . . . . . 19Gilead Ltd. (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25GlaxoSmithKline (UK) . . . . . . . . . . . . . . . . . . . . . . . 25, 69

Horizon discovery Ltd. (uK) . . . . . . . . . . . . . . . . . . . . . 25

idorsia (cH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70inKEF capital (nL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66intervac aB (SE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67ionis pharmaceuticals (uSa) . . . . . . . . . . . . . . . . . . . . . . 71

Janssen Biotech inc. (uSa) . . . . . . . . . . . . . . . . . . . . . . . 20Jennewein Biotechnologie GmbH (DE) . . . . . . . . . . . . . . 20

Kite pharma (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25Lundbeckfond Ventures (dK) . . . . . . . . . . . . . . . . . . . . . 66

medical prognosis institute a/S (dK) . . . . . . . . . . . . . . . . 66MediGene AG (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 71merck & co. (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 25Merck KGaA (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25mesoblast Ltd. (au) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82mobidiag oy (Fi) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67Molecular Partners AG (CH) . . . . . . . . . . . . . . . . . . . . . . 70molmed (it) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69Mologen AG (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19monsanto (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . 77, 78, 79MorphoSys AG (DE) . . . . . . . . . . . . . . . . . . . . . . . . . 68, 71mymetics S.a. (cH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70

nestle S.a. (cH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25Neurimmune AG (CH) . . . . . . . . . . . . . . . . . . . . . . . 71, 75nmd pharma a/S (dK) . . . . . . . . . . . . . . . . . . . . . . . . . . 66nordic Life Science day (SE) 2018 . . . . . . . . . . . . . . . . . 41nova-Institut GmbH (DE) . . . . . . . . . . . . . . . . . . . . . . . . 29Novartis AG (CH) . . . . . . . . . . . . . . . . . . . . . 22, 23, 71, 72novo nordisk a/S (dK) . . . . . . . . . . . . . . . . . . . . . . . . . . 13novo Seeds (dK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66novozymes a/S (dK) . . . . . . . . . . . . . . . . . . . . . . . . 25, 31ntc pharma (it) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72nufarm Ltd. (au) . . . . . . . . . . . . . . . . . . . . . . . . . . . 78, 79

oncoarendi therapeutics Sa (pL) . . . . . . . . . . . . . . . . . . 74oncology Venture Sweden aB (SE) . . . . . . . . . . . . . . . . . 66opiS s.r.l. (it) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19orchard therapeutics (uK/uSa) . . . . . . . . . . . . . . . . . . . 69ose immunotherapeutics Sa ( . . . . . . . . . . . . . . . . . . . . 69osiris therapeutics (uSa) . . . . . . . . . . . . . . . . . . . . . . . . 82otsuka pharmaceutical

pepsico. (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10Pfizer (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 19polpharma Biologics (pL) . . . . . . . . . . . . . . . . . 34, 35, cp4polyphor Ltd. (cH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70Procter & Gamble (USA) . . . . . . . . . . . . . . . . . . . . . . . . . 25Promocell GmbH (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . 89puretech Health plc (uSa) . . . . . . . . . . . . . . . . . . . . . . . 75

Qiagen nV (dE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71

reckitt Benckiser (uK) . . . . . . . . . . . . . . . . . . . . . . . . . . 25redx pharma (uK) . . . . . . . . . . . . . . . . . . . . . . . . . . 68, 75regeneron pharmaceuticals inc. (uSa) . . . . . . . . . . . 19, 21Rentschler Biotechnologie GmbH (DE) . . . . . . . . . . . 36, 75Roche Group (CH) . . . . . . . . . . . 15, 16, 17, 19, 21, 25, 71roche Venture Fund (cH) . . . . . . . . . . . . . . . . . . . . . . . . 66

Sangamo Biosciences inc. (uSa) . . . . . . . . . . . . . . . . . . 16Sanifit (ES) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72Sanofi SA (F) . . . . . . . . . . . . . . . . . . . . . . . . 13, 21, 25, 75Servier (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69Shimadzu (dE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . cp2Shire plc (irL) . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 16, 69Shuwen Biotech (cn) . . . . . . . . . . . . . . . . . . . . . . . . . . . 69Siemens Healthineers (dE) . . . . . . . . . . . . . . . . . . . . . . . 25Solvo Biotechnology sro (Hun) . . . . . . . . . . . . . . . . . . . 74Sophia Genetics (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . 65Sotio a.s. (cZ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74Springvest (Fi) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67Sunshine Kaidi Finland new Energy co. oy (cn/Fin) . . 67Syngenta AG (CH) . . . . . . . . . . . . . . . . . . . . . . . 77, 78, 79

takeda pharma a/S (dK) . . . . . . . . . . . . . . . 13, 16, 69, 82targovax aS (no) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20tech4Freedom (ES) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73thrombogenics (B) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19TiGenix (B) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81, 82trianni, inc. (uSa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15tVm capital Life Science (dE) . . . . . . . . . . . . . . . . . . 9, 68

uniQure BV (nL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

Versli Lietuva (Lt) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35Vertex pharmaceuticals inc. (uSa) . . . . . . . . . . . . . . . . . 20Vetter Pharma-Fertigung GmbH & Co.KG . . . . . . . . . . . . 21Vifor Pharma AG (AT) . . . . . . . . . . . . . . . . . . . . . . . . . . . 70Vivet therapeutics (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . 67

Wilhelm Bähren GmbH & Co. KG (DE) . . . . . . . . . . . . . 33Wilson therapeutics aB (SE) . . . . . . . . . . . . . . . . . . . . . . 67

promocELL promoKine’s angiogenesis assay Kit provides a simple, robust, easy to perform and semi-quantitative method to determine angiogenesis in vitro in less than 18 hours. it can be used for screen-ing of angiogenesis modulators or studies of angiogenesis related signal transduction. the assay is based on the measurement of the ability of endothelial cells to form 3d structures (tube formation) under the influ-ence of distinct stimulators, and uses a pro-prietary endotoxin-free and growth factor-reduced Extracellular matrix Solution.

the cell migration/chemotaxis assay Kits are easy to use, sensitive and high throughput-adaptable systems. they uti-

Cancer research

lize a Boyden chamber, where the cells migrate through a semi-permeable mem-brane (three different pore sizes available) in response to stimulatory or inhibitory compounds.

the cell invasion assay Kits also utilize a Boyden chamber that is coated with a lay-er of BmE (Basement membrane Extract), laminin, fibronectin, Collagen I or Colla-gen iV. the cells first traverse the matrix and then migrate through the semi-perme-able membrane in the Boyden chamber in response to different stimuli. cell migration as well as cell invasion can be analysed di-rectly using a fluorescence plate reader. D

contactPromoCell GmbHSickingenstr 63/65, 69126 Heidelbergwww.promokine.infoinfo@promokine.info

FREE EXCERPT

Save the date: On 14 and 15 March 2019, the Berlin Conference will once again be the meeting place for Life Science decision makers, business devel-opers, investors and legal experts. The conference will explore the exciting market for the development of novel antimicrobials and AMR diagnostics.

Find more information at:

www.berlin-conferences.com

Novel Antimicrobialsand AMR Diagnostics

12th Berlin Conference on Life Sciences

14.|15.3.2019

BIOCOM AG I Lützowstraße 33–36 I 10785 Berlin | Germanyevents@biocom.de I Tel. +49 (0)30 264921-53 I www.biocom.de

Own CHOBC® platform

mABs

New AB formats

Proteins

Drug substance and Fill&Finish

www.polpharmabiologics.comonestopshop@polpharma.com

����������� �����������

���� ����������-����-����

��� ������������������

���� ���� �����������(����� ������)

���-����� ������� ����������� ���

���-����� ������� ����������� ���

���������� �����������

����� ������������� �����������

(50-1000�)

����� ����� ����������

�������������

��� �������������(2000�)